🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 30/12/2002 | 15,70 | 16,39 | 15,68 | 15,76 | -1,81% | 4,52% | 473.400 |
| 27/12/2002 | 16,39 | 16,60 | 15,83 | 16,05 | -3,31% | 4,70% | 295.900 |
| 26/12/2002 | 16,73 | 16,97 | 16,46 | 16,60 | -0,78% | 3,05% | 184.600 |
| 24/12/2002 | 16,78 | 17,01 | 16,65 | 16,73 | -0,48% | 2,15% | 92.100 |
| 23/12/2002 | 16,67 | 17,00 | 16,48 | 16,81 | +0,84% | 3,12% | 363.700 |
| 20/12/2002 | 16,90 | 17,15 | 16,45 | 16,67 | +0,36% | 4,14% | 485.600 |
| 19/12/2002 | 16,93 | 17,44 | 16,33 | 16,61 | -1,60% | 6,56% | 510.600 |
| 18/12/2002 | 16,95 | 17,16 | 16,75 | 16,88 | -0,41% | 2,42% | 374.300 |
| 17/12/2002 | 16,77 | 17,24 | 16,72 | 16,95 | +0,95% | 3,10% | 316.800 |
| 16/12/2002 | 16,18 | 17,00 | 16,06 | 16,79 | +3,83% | 5,81% | 643.300 |
| 13/12/2002 | 16,69 | 16,76 | 16,12 | 16,17 | -2,77% | 3,83% | 298.000 |
| 12/12/2002 | 16,64 | 17,30 | 16,34 | 16,63 | +0,18% | 5,77% | 416.700 |
| 11/12/2002 | 16,37 | 16,69 | 16,22 | 16,60 | +0,30% | 2,87% | 333.000 |
| 10/12/2002 | 16,64 | 17,37 | 16,31 | 16,55 | -0,60% | 6,37% | 507.800 |
| 09/12/2002 | 17,42 | 17,56 | 16,39 | 16,65 | -4,48% | 6,72% | 647.400 |
| 06/12/2002 | 17,25 | 17,85 | 17,07 | 17,43 | +0,52% | 4,52% | 333.400 |
| 05/12/2002 | 17,86 | 18,09 | 17,33 | 17,34 | -2,36% | 4,26% | 270.700 |
| 04/12/2002 | 18,18 | 18,26 | 17,62 | 17,76 | -2,74% | 3,52% | 617.900 |
| 03/12/2002 | 19,06 | 19,06 | 18,21 | 18,26 | -4,20% | 4,46% | 404.200 |
| 02/12/2002 | 18,70 | 19,26 | 18,50 | 19,06 | +2,64% | 4,06% | 672.200 |
| 29/11/2002 | 18,45 | 18,80 | 18,44 | 18,57 | +1,03% | 1,95% | 229.700 |
| 27/11/2002 | 17,72 | 18,80 | 17,63 | 18,38 | +4,43% | 6,60% | 392.600 |
| 26/11/2002 | 18,89 | 18,89 | 17,60 | 17,60 | -7,51% | 6,83% | 512.700 |
| 25/11/2002 | 18,96 | 19,29 | 18,50 | 19,03 | +1,66% | 4,17% | 387.900 |
| 22/11/2002 | 18,63 | 19,28 | 18,40 | 18,72 | +0,11% | 4,72% | 595.100 |
| 21/11/2002 | 17,99 | 18,93 | 17,90 | 18,70 | +4,00% | 5,73% | 937.300 |
| 20/11/2002 | 17,45 | 18,04 | 17,42 | 17,98 | +2,63% | 3,55% | 570.700 |
| 19/11/2002 | 17,89 | 18,21 | 17,33 | 17,52 | -2,12% | 4,92% | 581.500 |
| 18/11/2002 | 17,29 | 18,18 | 17,25 | 17,90 | +4,50% | 5,38% | 714.300 |
| 15/11/2002 | 17,28 | 17,66 | 17,13 | 17,13 | -1,89% | 3,07% | 718.900 |